Navigation Links
Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
Date:11/21/2007

SEATTLE, Nov. 21 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that Dr. Peter Thompson, president, chief executive officer and chairman of Trubion, is scheduled to present a corporate update at the upcoming Lazard Capital Markets Healthcare Investor Conference to be held at The New York Palace Hotel. Dr. Thompson is scheduled to present Nov. 27, 2007, at 2:30 p.m. Interested parties may access the live audio webcast of the presentation by visiting the Wall Street Webcasting link at http://www.wsw.com/webcast/lz4/trbn.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP(TM) custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information, visit

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014   Propeller Health , ... announced the hire of Brad Towle as ... be responsible for driving the company,s sales growth, customer ... in healthcare, and specifically his past role in the ... the company at this pivotal time in the industry," ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
(Date:7/26/2014)... NY (PRWEB) July 26, 2014 ... provides key market data on the Canada Endoscopy ... millions of US dollars, volume (in units) and ... - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization ... Full Report at http://www.marketresearchreports.biz/analysis/213254 . , The ...
(Date:7/25/2014)... study by researchers from the University of Leicester ... function, unlocking the potential to create new materials ... has been published in the prestigious academic journal ... laser technique to examine in rich detail the ... cluster containing an acetylene molecule and a single ...
Breaking Biology Technology:Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2InterMune to Release Second Quarter Financial Results on August 6 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3
... , , CAMBRIDGE, Mass., Aug ... ), the global specialty biopharmaceutical company, announces today that it ... a leading player in RNA-based therapeutics, to develop its proprietary ... diseases, thereby enabling Shire to build on its already strong ...
... KVISTGAARD, Denmark, August 24 Bavarian Nordic,A/S ... have initiated,negotiations for a new contract to develop ... potential new project will have no,influence on the ... contract for the procurement of 20 million doses ...
... ... lab workhorse delivers high resolution and sensitivity , ... Surrey, British Columbia (PRWEB) August 24, ... for life science and industrial applications, has announced the release of the EXi ...
Cached Biology Technology:Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform 2Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform 3Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform 4Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R) 2QImaging Introduces EXi Aqua™ Microscopy Camera for Bio-Imaging 2QImaging Introduces EXi Aqua™ Microscopy Camera for Bio-Imaging 3
(Date:7/28/2014)... has identified areas of the Earth that are high ... , Europe is particularly vulnerable, as it has the ... cent, of any continent in ,refugia, areas of ... conditions remain relatively constant during times of great environmental ... mostly in Scandinavia and Scotland. , The biggest ...
(Date:7/28/2014)... new tool that can help advance the genetic ... renewable bioenergy, has been developed by researchers with ... Institute (JBEI), a multi-institutional partnership led by Lawrence ... have developed an assay that enables scientists to ... transporters, critical components in the biosynthesis of plant ...
(Date:7/28/2014)... using statistical tools to map social connections in ... observational techniques, shedding light on prairie dog communities ... plague and guide future conservation efforts. The work ... University and the National Evolutionary Synthesis Center (NESCent). ... subject to bubonic plague," says Dr. Jennifer Verdolin, ...
Breaking Biology News(10 mins):Study finds Europe's habitat and wildlife is vulnerable to climate change 2How sweet it is 2How sweet it is 3Social network research may boost prairie dog conservation efforts 2
... green initiatives received a welcome boost Jan. 21 when ... environmentally friendly solar utility vehicle as part of a ... and student success. "We are proud to support ... programs as part of its vital efforts to attract ...
... is no good evidence supporting a harmful effect of exercise ... exercise, according to a review of studies published in this ... Exercise is an extremely popular leisure-time activity in many countries ... of the modern lifestyle. It is widely promoted in as ...
... studies have shown that breastfeeding appears to reduce the ... study led by a University of Alberta professor has ... twice a week negated the beneficial effects that breastfeeding ... The article appears online in the international journal ...
Cached Biology News:$300,000 donation from BP includes solar vehicle for UH 2Fast-food diet cancels out benefits of breastfeeding in preventing asthma 2
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SSA (Sheep serum albumin) lysine through amide bonds. This product is homologous to NP-BSA....
Antibodies were affinity purified using epitopes specific to Alpha4 immobilized on solid support....
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
Biology Products: